GE Healthcare joined the ranks of believers in mega-slice PET/CT with the formal release of its Discovery VCT on the RSNA exhibit floor. The 64-slice hybrid, shown as a work in progress at the 2004 meeting, will compete with the Siemens biograph 64 and Philips Gemini GXL, both 64-slice PET/CT scanners launched one year ago.
GE Healthcare joined the ranks of believers in mega-slice PET/CT with the formal release of its Discovery VCT on the RSNA exhibit floor. The 64-slice hybrid, shown as a work in progress at the 2004 meeting, will compete with the Siemens biograph 64 and Philips Gemini GXL, both 64-slice PET/CT scanners launched one year ago.
Over the past several years, PET/CT has been widely adopted by the oncology community. Hybrids configured with 64-slice CTs may pave the way to a new cardiology market for this technology. GE's new Discovery VCT is being targeted specifically for cardiac applications.
Sixty-four-slice CTs show extraordinary detail in coronary CTA and promise to complement functional assessments of the heart possible with PET. Slowing the adoption of this technology, however, will be the lack of an optimal PET imaging agent for cardiac applications.
Rubidium currently supports myocardial perfusion studies with PET, but it is costly and cumbersome to produce. The radionuclide is created at clinical sites using a "generator" - radioactive strontium that rapidly decays into rubidium.
GE, a pioneer of hybrid imaging, has invested more than $160 million in the
research and development of hybrid imaging technology, according to the company, and holds 25 related patents. The company launched the era of fusion imaging in 1999 with its SPECT/CT Millennium VG Hawkeye. Its PET/CT Discovery LS followed two years later.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the recent RSNA conference.
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.